open access

Vol 12, No 4 (2017)
Heart failure
Published online: 2017-06-19
Get Citation

Candidate for new heart failure and reduced ejection fraction therapy — angiotensin receptor-neprilysin inhibitor (ARNI). Clinician’s guide

Anna Chuda, Małgorzata Lelonek
DOI: 10.5603/FC.a2017.0048
·
Folia Cardiologica 2017;12(4):397-404.

open access

Vol 12, No 4 (2017)
Heart failure
Published online: 2017-06-19

Abstract

The European Society of Cardiology (ESC) introduced a new class of drugs — ARNI (angiotensin receptor-neprilysin inhibitor) in patients with heart failure and reduced ejection fraction (HFrEF) (class I, level of evidence B) in the recently published guidelines for heart failure (HF), published in 2016. The only representative of ARNI is sacubitril/valsartan. Based on the results of the PARADAGIM-HF study, sacubitril/valsartan is recommended instead of angiotensin-converting enzyme inhibitors (ACEI) to further reduce the risk of death and hospitalization because of HF in outpatients with stable HFrEF, with symptomatic HF (NYHA II–IV) persist despite optimal treatment with ACEI (or angiotensin II receptor antagonists), beta-adrenolytic and mineralocorticoid receptor antagonist. The paper presents case report of first 2 patients with HFrEF who sacubitril/valsartan therapy was initiated.

Abstract

The European Society of Cardiology (ESC) introduced a new class of drugs — ARNI (angiotensin receptor-neprilysin inhibitor) in patients with heart failure and reduced ejection fraction (HFrEF) (class I, level of evidence B) in the recently published guidelines for heart failure (HF), published in 2016. The only representative of ARNI is sacubitril/valsartan. Based on the results of the PARADAGIM-HF study, sacubitril/valsartan is recommended instead of angiotensin-converting enzyme inhibitors (ACEI) to further reduce the risk of death and hospitalization because of HF in outpatients with stable HFrEF, with symptomatic HF (NYHA II–IV) persist despite optimal treatment with ACEI (or angiotensin II receptor antagonists), beta-adrenolytic and mineralocorticoid receptor antagonist. The paper presents case report of first 2 patients with HFrEF who sacubitril/valsartan therapy was initiated.

Get Citation

Keywords

heart failure, angiotensyn II receptor antagonist and neprilysin inhibitor, ARNI

About this article
Title

Candidate for new heart failure and reduced ejection fraction therapy — angiotensin receptor-neprilysin inhibitor (ARNI). Clinician’s guide

Journal

Folia Cardiologica

Issue

Vol 12, No 4 (2017)

Pages

397-404

Published online

2017-06-19

DOI

10.5603/FC.a2017.0048

Bibliographic record

Folia Cardiologica 2017;12(4):397-404.

Keywords

heart failure
angiotensyn II receptor antagonist and neprilysin inhibitor
ARNI

Authors

Anna Chuda
Małgorzata Lelonek

References (12)
  1. Niewydolność serca w Polsce — raport 2016. Materiały informacyjne Sekcji Niewydolności Serca PTK. http://www.niewydolnosc-serca.pl/barometr.pdf (9.05.2017).
  2. Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129–2200.
  3. Sobczak S, Lelonek M. LCZ696 przełomem w leczeniu przewlekłej niewydolności serca z obniżoną frakcją wyrzutową lewej komory. Folia Cardiol. 2016; 10(6): 403–409.
  4. Lelonek M. Niewydolność serca i powtarzające się hospitalizacje. Folia Cardiol. 2016; 11(1): 37–46.
  5. Entresto™. Charakterystyka Produktu Leczniczego 2015.
  6. Hussar DA, Abdelsayed M. Sacubitril/valsartan, ivabradine hydrochloride, alirocumab, and evolocumab. J Am Pharm Assoc. 2015; 55(6): 674–678.
  7. McMurray JJV, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11): 993–1004.
  8. Farmakis D, Bistola V, Karavidas A, et al. Practical considerations on the introduction of sacubitril/valsartan in clinical practice: current evidence and early experience. Int J Cardiol. 2016; 223: 781–784.
  9. McMurray JJV, Packer M, Desai AS, et al. PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013; 15(9): 1062–1073.
  10. Desai AS, McMurray JJV, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015; 36(30): 1990–1997.
  11. Lelonek M. The need to apply the best therapy in heart failure — the era after PARADIGM-HF. Arch Med Sci. https://www.termedia.pl/The-need-to-apply-the-best-therapy-in-heart-failure-the-era-after-PARADIGM-HF,19,27495,1,1.html (9.05.2017).
  12. Senni M, McMurray JJV, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016; 18(9): 1193–1202.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl